COMMUNIQUÉS West-GlobeNewswire

Triastek's 3D Printed Gastric Retention Product T22 Receives FDA Clearance of IND Application
31/01/2024
NANJING, CHINA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Triastek ' s 3D printed gastric retention product T22 received IND clearance from the FDA, becoming the world ' s first 3D printed gastric retention product. Currently, [...]
MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
31/01/2024
CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, [...]
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
31/01/2024
BETHESDA, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain,” or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, [...]
Launching our most comprehensive test and expanding into new global markets
31/01/2024
MELBOURNE, Australia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE), is at the forefront in personalised predictive genomics, reshaping the healthcare landscape with its inventive [...]
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
31/01/2024
Insulin resistance (IR), a common feature of childhood obesity which affects 15 million children and adolescents, is the main driver of obesity-related metabolic complications such as Type 2 diabetes, hypertension, and [...]
Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer’s disease
31/01/2024
Neurimmune aims to develop aducanumab-based therapeutics that can be subcutaneously administered ZURICH, Switzerland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Neurimmune announced today that it regained global rights to [...]
Novo Nordisk files annual report with the SEC
31/01/2024
Bagsværd, Denmark, 31 January 2024 – Novo Nordisk A/S has filed its Annual Report 2023 on Form 20-F for the financial year 2023 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of [...]
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
31/01/2024
23ME-01473 (‘1473) seeks to treat cancer by restoring anti-tumor immunity through NK and T cells ‘1473 has dual mechanisms of blocking the immunosuppressive effects of soluble ULBP6, and inducing Fc receptor-mediated [...]
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
31/01/2024
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced [...]
Protara Therapeutics to Participate in Upcoming Investor Conferences
31/01/2024
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
Agrify Receives Positive Nasdaq Listing Determination
31/01/2024
TROY, Michigan, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today [...]
Biogen to Realign Resources for Alzheimer's Disease Franchise
31/01/2024
Company to reprioritize resources allocated to ADUHELM ® (aducanumab-avwa) to advance LEQEMBI ® (lecanemab-irmb) and to develop new treatment modalities Biogen committed to building a leading Alzheimer’s disease [...]
Plus de capacités en faveur des clients : Olon va ouvrir une nouvelle unité de production d'IPA hautement actifs aux États-Unis
31/01/2024
MILAN, Italie, 31 janv. 2024 (GLOBE NEWSWIRE) -- Le groupe Olon annonce la construction d'une unité de production de pointe d'ingrédients pharmaceutiques actifs (IPA) hautement actifs. L'unité de production d' [...]
Trinity Biotech Announces Q3 2023 Financial Results & Business Update
31/01/2024
-Investor call to be held today at 8:30 am EST DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023. [...]
Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India
31/01/2024
DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced that it has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous [...]
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
31/01/2024
STAMFORD, Conn., Jan. 31, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management [...]
Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of Science
31/01/2024
Partnership represents firm’s second international collaboration and provides access to groundbreaking research taking place within world’s fifth largest pharmaceutical market CINCINNATI, Jan. 31, 2024 (GLOBE NEWSWIRE [...]
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
31/01/2024
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report [...]
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
31/01/2024
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal [...]

Pages